|
| |
Press Releases
NIH Scientists Identify Gene for Fatal Childhood Disorder, Niemann-Pick Type CThursday, July 10, 1997Bethesda, MD -- After decades of work, scientists at the National Institutes of Health have identified a gene alteration associated with the fatal childhood cholesterol disorder Niemann-Pick type C (NPC). Learning how the gene functions may lead to the first effective treatment for the disease and to a fundamental new understanding of how cholesterol is processed in the body.
Scientists Isolate "Crown Jewel"--Huntington's Disease GeneTuesday, March 23, 1993Scientists have identified the genetic mutation that causes Huntington's disease (HD), a fatal, neurodegenerative disorder characterized by progressive physical and mental deterioration. The discovery, to be reported in the March 26 issue of Cell,* is the culmination of a 10-year-long collaboration between investigators in six laboratory groups around the world with major support from the National Institute of Neurological Disorders and Stroke (NINDS).
Scientists Link Fatal, Cholesterol-Storage Disorder to Chromosome 18Monday, March 01, 1993Scientists at the National Institute of Neurological Disorders and Stroke (NINDS) have linked a deadly brain disorder, called Niemann-Pick Type C disease, to a small region of human chromosome 18. These findings, reported in the current issue of Proceedings of the National Academy of Sciences,* may eventually lead to improved diagnosis and treatment for this inherited disorder and yield new insight into the metabolism of cholesterol inside the body's cells.
DATATOP Study Confirms Deprenyl's Efficacy in Fighting the Progression of Parkinson's DiseaseWednesday, January 20, 1993Scientists announced today in the January 21 New England Journal of Medicine the results of a broad, long-term study on the effects of deprenyl and tocopherol (a form of vitamin E) on the progression of early Parkinson's disease. The investigators, who comprise a group known as the Parkinson's Study Group, confirmed that deprenyl is effective in slowing the early progression of Parkinson's disease and delaying the need for initiation of therapy with the drug levodopa. The latest results of the study showed, however, that the beneficial effects of deprenyl were not as lasting in fighting Parkinson's disease as the investigators had anticipated when evaluating the preliminary results in 1989. The clinical trials also showed no evidence that tocopherol was useful in Parkinson's disease.
|
|
